Banner - Collaborative Care Symposium

News

Clinicians share their thoughts on the roles of a dual-acting antihistamine/mast cell stabilizer and topical ester corticosteroid in the management of seasonal allergic conjunctivitis.

Utilizing a red eye protocol can be helpful in the determination of whether conjunctivitis is allergic, viral, or bacterial.

Recent data show that although ocular allergies are common, the majority of sufferers do not seek medical help beyond over-the-counter drugs.

Patients who receive intravitreal ranibizumab (Lucentis, Genentech) for treatment of diabetic macular edema over a 3-year period achieved rapid improvements in vision and edema.

The financial feasibility of using only one laser for all procedures is a given. Arun C. Gulani, MD, takes this one step further, arguing that perhaps the future may hold cases in which use of the femtosecond laser is a necessity, becoming a standard-of-care concept.

There is a moralistic responsibility that all eye-care professionals should follow to make sure their patients choose the correct eyewear to prevent injury, especially when the patients are children.

Patients with open-angle glaucoma (OAG) had a significant reduction in IOP and did not require anti-glaucoma medications over 1 year postoperatively when micro-invasive glaucoma surgery (MIGS) was performed, according to interim results for a MIGS study group that were reported by David F. Chang, MD.

Bausch + Lomb and TheraPearl LLC have announced the creation of the Bausch + Lomb THERA°PEARL Eye Mask, a product aimed at those suffering from a variety of common ailments, including the most common type of dry eye.

InnFocus Inc. has received authorization from the FDA to begin the phase I trial of the InnFocus MicroShunt to treat open-angle glaucoma (OAG).

Ophthalmologists are nearing a crossroads with the replacement of phacoemulsification by femtosecond laser technology. New femtosecond laser technology is costly, and surgeons must decide if this technology is right for their practices, explained John Vukich, MD.

Alcon Research Ltd. has accused Mylan Inc. of seeking government approval for a drug that would infringe three of its patents for a glaucoma treatment.

Omeros Corp. has announced that it recently submitted a new drug application to the FDA for approval of a new drug for use in patients undergoing IOL replacement (ILR) surgery.

Practicing reverse motivation may be just what the doctor ordered when it comes to helping staff members achieve their goals, relates columnist Dianna Graves.

Toric IOL implantation provides a reliably effective method for reducing existing astigmatism in patients undergoing cataract surgery, but careful marking of the eye to guide accurate axis alignment of the IOL is essential for achieving good outcomes, said Bonnie An Henderson, MD.

A new +2.5 D add version of a multifocal IOL features a re-designed optic that enhances visual function at intermediate and distance and delivers excellent visual quality.

Ophthalmology Times introduces this new series called “Gloves Off with Gulani” that is part of the full-spectrum concept of a “super-specialty,” in which Arun C. Gulani, MD, will present prototype case studies and accept input to show how every case-no matter how difficult-deserves a mindset of emmetropia. Look for the first “gloves-off” encounter-“Multifocal IOL nightmare: Reversed to 20/20”-in the Oct. 1 issue of Ophthalmology Times.

A light-adjustable IOL continues to show potential for delivering customized vision with predictable results.

While manual limbal relaxing incisions and femtosecond femtosecond astigmatic keratotomies can address mild to moderate astigmatism, toric IOLs are quite effective at all ranges of astigmatism, relates one surgeon.

A single-piece hydrophobic acrylic IOL has many features that make it a good choice for a monofocal implant in routine and challenging cataract surgery cases.

The Transparency Commission of the French National Authority for Health has issued a favorable opinion for the reimbursement and hospital listing of Alimera Sciences’ fluocinolone acetonide intravitreal implant (Iluvien) for the treatment of chronic diabetic macular edema.